Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma

Zhu, Jay Jiguang; Demireva, Petya; Kanner, Andrew A.; Pannullo, Susan C.; Mehdorn, Maximilian; Avgeropoulos, Nicholas G.; Salmaggi, Andrea; Silvani, Antonio; Goldlust, Samuel; David, Carlos A.; Benouaich‐Amiel, Alexandra

doi:10.1007/s11060-017-2601-y

Cited by 50 publications

(34 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 18 Based on the interim analysis, there is no preliminary evidence that health-related quality of life, cognitive, or functional status is adversely affected by continuous usage of TTF. 19 …”

Section: Introductionmentioning

confidence: 99%

Radiotherapy of glioblastoma 15 years after the landmark Stupp’s trial: more controversies than standards?

Kazda

Dziacky

Burkoň

et al. 2018

Radiology and Oncology

View full text Add to dashboard Cite

BackgroundThe current standard of care of glioblastoma, the most common primary brain tumor in adults, has remained unchanged for over a decade. Nevertheless, some improvements in patient outcomes have occurred as a consequence of modern surgery, improved radiotherapy and up-to-date management of toxicity. Patients from control arms (receiving standard concurrent chemoradiotherapy and adjuvant chemotherapy with temozolomide) of recent clinical trials achieve better outcomes compared to the median survival of 14.6 months reported in Stupp’s landmark clinical trial in 2005. The approach to radiotherapy that emerged from Stupp’s trial, which continues to be a basis for the current standard of care, is no longer applicable and there is a need to develop updated guidelines for radiotherapy within the daily clinical practice that address or at least acknowledge existing controversies in the planning of radiotherapy.The goal of this review is to provoke critical thinking about potentially controversial aspects in the radiotherapy of glioblastoma, including among others the issue of target definitions, simultaneously integrated boost technique, and hippocampal sparing.ConclusionsIn conjunction with new treatment approaches such as tumor-treating fields (TTF) and immunotherapy, the role of adjuvant radiotherapy will be further defined. The personalized approach in daily radiotherapy practice is enabled with modern radiotherapy systems.

show abstract

Section: Introductionmentioning

confidence: 99%

Radiotherapy of glioblastoma 15 years after the landmark Stupp’s trial: more controversies than standards?

Kazda

Dziacky

Burkoň

et al. 2018

Radiology and Oncology

View full text Add to dashboard Cite

show abstract

“…The transducer arrays that deliver TTFields cause scalp lesions, which can be managed by shifting the array positions on the scalp during array changes. There were no reports of systemic side effects from TTFields when combined with TMZ (32), neither was there evidence that continuous use of TTFields adversely affected quality of life, cognition, or functional status (33, 34).…”

Section: Discussionmentioning

confidence: 99%

Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study

Rao

Zhu

et al. 2019

Front. Neurol.

Self Cite

View full text Add to dashboard Cite

Clinical studies treating pediatric and adult solid tumors, such as glioblastoma (GBM), with a triple-drug regimen of temozolomide (TMZ), bevacizumab (BEV), and irinotecan (IRI) [TBI] have demonstrated various efficacies, but with no unexpected toxicities. The TBI regimen has never been studied in recurrent GBM (rGBM) patients. In this retrospective study, we investigated the outcomes and side effects of rGBM patients who had received the TBI regimen. We identified 48 adult rGBM patients with a median age of 56 years (range: 26–76), who received Tumor Treating Fields (TTFields) treatment for 30 days or longer, and concurrent salvage chemotherapies. The patients were classified into two groups based on chemotherapies received: TBI with TTFields (TBI+T, N = 18) vs. bevacizumab (BEV)-based chemotherapies with TTFields (BBC+T, N = 30). BBC regimens were either BEV monotherapy, BEV+IRI or BEV+CCNU. Patients in TBI+T group received on average 19 cycles of TMZ, 26 and 21 times infusions with BEV and IRI, respectively. Median overall survival (OS) and progression-free survival (PFS) for rGBM (OS-R and PFS-R) patients who received TBI+T were 18.9 and 10.7 months, respectively. In comparison, patients who received BBC+T treatment had OS-R and PFS-R of 11.8 (P > 0.05) and 4.7 (P < 0.05) months, respectively. Although the median PFS results were significantly different by 1.5 months (6.6 vs. 5.1) between TBI+T and BBC+T groups, the median OS difference of 14.7 months (32.5 vs. 17.8) was more pronounced, P < 0.05. Patients tolerated TBI+T or BBC+T treatments well and there were no unexpected toxicities. The most common side effects from TBI+T treatment included grade III hypertension (38.9%) and leukopenia (22.2%). In conclusion, the TBI regimen might play a role in the improvement of PFS-R and OS-R among rGBM patients. Prospective studies with a larger sample size are warranted to study the efficacy and toxicity of TBI+T regimen for rGBM.

show abstract

“…Second group was better in quality of life for first 9 months and other characterizations for comparative evaluation were similar. TTF group had reported just ithcy skin [2].…”

Section: Discussionmentioning

confidence: 99%

Tumor treating fields for glioblastoma: Review

Uysal¹

2017

Neurol Disord Therap

View full text Add to dashboard Cite

Tumor treating fields (TTF) is delivered with an original device causing antimitotic activity in tumor cells of glioblastoma patients. Low intensity and intermediate frequency alternating electric fields are effective over metaphase. Tumor treating fields is a novel modality approved by FDA (Federal Drug Association) for newly diagnosed and also recurrent glioblastoma. Frequency of 200 kHz is given with transducer applied on scalp of patient. Phase 3 trial showed the efficacy of this modality alone equivalent compared to chemotherapy. Skin toxicity is the major side effect of this therapy. TTF is now used in recurrent glioblastoma but future perspective shows that this unique modality can be delivered in different solid tumors.

show abstract

Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma

Cited by 50 publications

References 31 publications

Radiotherapy of glioblastoma 15 years after the landmark Stupp’s trial: more controversies than standards?

Radiotherapy of glioblastoma 15 years after the landmark Stupp’s trial: more controversies than standards?

Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study

Tumor treating fields for glioblastoma: Review

Contact Info

Product

Resources

About